Pharmacokinetics of Anti-tuberculosis Drugs in Gastrectomized Patients
Pharmacokinetics of Anti-tuberculosis Drugs in Gastrectomized Patients
The purpose of this study is to evaluate the effect of gastrectomy on pharmacokinetic profile
 of first-line anti-tuberculosis drugs in patients with pulmonary tuberculosis (TB).
Gastrectomy is a well-known risk factor for TB. Also, there were some reports about
 malabsorption of anti-TB drugs in the gastrectomized patients. However, pharmacokinetics of
 recently used first line anti-TB drugs in the gastrectomized patients have not been well
 evaluated simultaneously. Therefore, the investigators aim to evaluate the effect of
 gastrectomy on pharmacokinetic profile of first-line anti-TB drugs in patients with pulmonary
 TB through this study.
Inclusion Criteria:

 1. Age greater than 18 years and less than 80 years

 2. pulmonary TB confirmed by microbiologic test such as AFB culture or TB PCR

 3. usage of 4 first-line anti-TB drugs (Isoniazid(INH) Rifampin(RFP) Ethambutol(EMB),
 Pyrazinamide(PZA) = HREZ)

 Exclusion Criteria:

 1. patients with liver disease (bilirubin ≥ 1.5 mg/d or AST ≥ 2 x normal upper limit) or
 chronic renal failure (Cr ≥ 2.0 mg/d) who cannot use first-line anti-TB drugs

 2. patients with AIDS or hypoalbuminemia(albumin < 3.0g/dl)that will influence
 pharmacokinetics of first line anti-TB drugs

 3. patients using other drugs that will influence pharmacokinetics of first line anti-TB
 drugs during anti-TB treatment (e.g warfarin)

 4. patients using anti-cancer or immunosuppressive agents that will influence the
 response of pulmonary TB to anti-TB drugs

 5. discontinuation of first-line anti-TB drugs(HREZ)due to side effect or resistance

 6. follow-up loss before completion of anti-TB treatment

 7. any condition making the patients undergo gastrectomy during anti-TB treatment in case
 of Non-gastrectomy group